Log in

NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, Forecast & News

$8.72
-0.34 (-3.75 %)
(As of 03/31/2020 02:21 AM ET)
Today's Range
$8.40
Now: $8.72
$9.30
50-Day Range
$4.06
MA: $8.05
$10.64
52-Week Range
$1.03
Now: $8.72
$10.75
Volume413,597 shs
Average Volume805,277 shs
Market Capitalization$326.56 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17
Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Read More
Avadel Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVDL
CUSIPN/A
Phone353-1485-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.22 million
Book Value($0.78) per share

Profitability

Net Income$-33,230,000.00

Miscellaneous

Employees144
Market Cap$326.56 million
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive AVDL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.


Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions

How has Avadel Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVDL shares have increased by 9.1% and is now trading at $8.72. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Avadel Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avadel Pharmaceuticals.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Avadel Pharmaceuticals.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) issued its quarterly earnings data on Thursday, March, 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.18. The company had revenue of $11 million for the quarter, compared to the consensus estimate of $11 million. Avadel Pharmaceuticals had a negative return on equity of 608.01% and a negative net margin of 56.11%. View Avadel Pharmaceuticals' earnings history.

What guidance has Avadel Pharmaceuticals issued on next quarter's earnings?

Avadel Pharmaceuticals updated its first quarter 2020 Pre-Market earnings guidance on Thursday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $10 million, compared to the consensus revenue estimate of $8.35 million.

What price target have analysts set for AVDL?

5 brokerages have issued 1-year price targets for Avadel Pharmaceuticals' shares. Their forecasts range from $6.00 to $15.00. On average, they anticipate Avadel Pharmaceuticals' share price to reach $11.00 in the next year. This suggests a possible upside of 26.1% from the stock's current price. View analysts' price targets for Avadel Pharmaceuticals.

Has Avadel Pharmaceuticals been receiving favorable news coverage?

News headlines about AVDL stock have been trending very negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avadel Pharmaceuticals earned a coverage optimism score of -3.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutAvadel Pharmaceuticals.

Are investors shorting Avadel Pharmaceuticals?

Avadel Pharmaceuticals saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 3,953,100 shares, a drop of 43.9% from the February 27th total of 7,050,000 shares. Based on an average trading volume of 712,600 shares, the days-to-cover ratio is presently 5.5 days. Currently, 11.4% of the company's stock are sold short. View Avadel Pharmaceuticals' Current Options Chain.

Who are some of Avadel Pharmaceuticals' key competitors?

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Chaarat Gold (CGH), Associated British Foods (ABF), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), First Data (FDC) and Cypress Semiconductor (CY).

Who are Avadel Pharmaceuticals' key executives?

Avadel Pharmaceuticals' management team includes the following people:
  • Mr. Michael F. Kanan, Sr. VP & CFO (Age 56)
  • Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
  • Mr. Gregory J. Divis, VP of Corp. and Bus. Devel. (Age 54)
  • Ms. Sandra L. Hatten, Sr. VP of Quality & Regulatory Affairs (Age 62)
  • Mr. Gregory J. Divis Jr., Interim Chief Exec. Officer (Age 52)

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $8.72.

How big of a company is Avadel Pharmaceuticals?

Avadel Pharmaceuticals has a market capitalization of $326.56 million and generates $59.22 million in revenue each year. The company earns $-33,230,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe. View additional information about Avadel Pharmaceuticals.

What is Avadel Pharmaceuticals' official website?

The official website for Avadel Pharmaceuticals is http://www.avadel.com/.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected]


MarketBeat Community Rating for Avadel Pharmaceuticals (NASDAQ AVDL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  560
MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel